ACCESS Newswire

CBD Life Sciences Inc.

Share
CBD Life Sciences, Inc. (CBDL) Debuts Delta-10 Cartridges

SCOTTSDALE, AZ / ACCESSWIRE / July 21, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding its product line with all-new Delta-10 Cartridges.

CBD Life Sciences Inc. is finally ready to debut two different strains of Delta-10 Cartridges. The two strains are Sour Diesel & Blue Dream, and both are 900MG for each one. Delta 10-THC or Delta 10-Tetrahydrocannabinol is a brand new, cutting edge cannabinoid (derived from Hemp) which carries similar psychoactive effects and euphoric feelings associated with the traditional cannabis use. Additionally, these cannabinoids are known for their anti-nausea, anti-anxiety, appetite stimulating and stress reducing properties. President & CEO Lisa Nelson stated "Delta-10 definitely has the power to change the CBD market dramatically!" This is going to be a top selling product for CBD Life Sciences Inc. online distribution in the upcoming weeks along with the Pain Relief Roll-On that launched on Amazon last week.

CBD Life Sciences Inc. surpasses the competition with the little amounts of extra ingredients we use. Sourcing only the best Delta 10 Distillate we then take the cleanest terpenes and infuse them to bring you these products that will not disappoint! Our new Delta 10 products are lab tested for quality both in the raw form and in the finished product. Delta 10-THC is superior to the traditional and illegal Delta 9-THC because it carries basically every benefit and effect of Delta 9-THC but is fully federally legal and legal in 38 states in the United States. Most clients opt for Delta 8 as their sleeping aid. They prefer Delta 10 when it comes to promoting greater creativity, energy, alertness, and euphoria. Delta 10 is generally uplifting and ideal for daytime use. It also can appeal to a mass audience interested in psychoactive advantages without fear of meeting delta 9's outcomes. It is safe to say that Delta 10 will become more popular since it provides enhanced focus without the paranoia of Delta 9.

CBD Life Sciences Inc. is getting close to its 3rd retail location along with a recreational marijuana facility. This will be significant as far as expansion and revenue go and CBD Life Sciences Inc. will keep the public informed moving forward.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Link to Greenhouse Video: https://streamable.com/yb7pyd

Link to Greenhouse Video 2: https://streamable.com/5md9ym

The number of benefits CBD has is tremendous! These benefits include help with behavioral/neurological complications such as ADD/ADHD, anxiety, autism, bipolar, OCD, PTSD, epilepsy, Parkinson's, osteoporosis, and ALS. CBD can also benefit pain management that can stem from headaches/migraines, arthritis, cramps, spinal injuries, and fibromyalgia. CBD has been found to also have gastrointestinal benefits with gastro-disorders and complications such as anorexia, cachexia, Crohn's, diabetes, and nausea. Physical complications/disorders such as muscular dystrophy and even immune system-based deficiencies and other complications such as cancer and hypertension even our bodies way and ability to maintain homeostasis have all been said to benefit from CBD.

LBC BIOSCIENCE INC. ONLINE STORE

LBC BIOSCIENCE'S Online Emporium

LBC Bioscience Inc. is well stocked already as it is with some very high-quality CBD offerings - all at very reasonable prices. Check out LBC Bioscience Inc's newest product offerings including its: 100MG CBD Bath Bombs in a variety of scents, Delta 8 Gummies, 1500 MG Premium Berry Drops, and a variety of all-new Skincare products. Or shop our top selling products (based on order frequency) which include our CBD Pain Cream, CBD Oils and CBD Pet Treats.

Become a Distributor

  • Large Selection of Products (over 50 items and growing)
  • 100% USA Made Products 'organic & kosher.'
  • All Products are THC-FREE (they contain 0.00% THC)
  • Weekly Deals (new deals every week)
  • 20% off on all products using code 'LBC20.'

LBC Bioscience Inc. accepts: Visa, MasterCard, American Express, Discover etc.

Shareholders and interest holders may also stay current with LBC Bioscience Inc Updates:

LBC Bioscience Inc's Main Website at www.lbcbioscienceinc.com
Twitter: https://www.twitter.com/lbcbioscience
Facebook: https://www.facebook.com/lbcbioscience
Instagram: https://www.instagram.com/lbcbioscience

Amazon: https://www.amazon.com/shops/lbcbioscienceinc

About LBC Bioscience Inc.
LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC has developed and is retailing/wholesale a full line of cannabidiol based organic products including CBD Drops, Gumballs, Honey Sticks, Pain Relief Creams, Anxiety & Sleep Supplements, Edibles, Coffee, Skincare Line, Pet Line, Tablets and more. LBC's products can be viewed and purchased on the Company's website at www.lbcbioscienceinc.com.

Ten Associates LLC
Contact: Thomas E. Nelson
Telephone: (480) 326-8577
Email: tenassociates33@gmail.com
Website: www.tenassociatesllc.com

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking

SOURCE: CBD Life Sciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/656378/CBD-Life-Sciences-Inc-CBDL-Debuts-Delta-10-Cartridges

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

GoodData Accelerates in Q4 with Product Innovation and Business Growth15.1.2026 10:55:00 CET | Press release

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 15, 2026 / GoodData, a leading AI-native decision intelligence platform, today announced strong Q4 results driven by record product development velocity, the launch of its Intelligence Layer for trustworthy AI, and continued expansion across the financial services sector. The quarter underscored GoodData's commitment to delivering inclusive, governed AI at scale, marked by significant accessibility milestones and sustained adoption among global enterprises. Business highlights GoodData's momentum accelerated throughout Q4, fuelled by a surge in development activity and deepening strategic partnerships. The company delivered a 50% year-on-year increase of product releases in Q4 2025 compared to Q4 2024, with a three-fold increase in AI-focused development activity in agentic workflows in H2. "Our performance in Q4 shows that speed and trust are not mutually exclusive," said Roman Stanek, CEO and Founder of GoodData. "With the launch

A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 202615.1.2026 09:00:00 CET | Press release

In Vienna, Enterprise Imaging offers the "Clinician-First" approach to keeping radiologists in their flow, spotlighting the human behind the innovation and empowering them to work in comfort with their technology. MORTSEL, BE / ACCESS Newswire / January 15, 2026 / At ECR 2026, AGFA HealthCare will unveil its latest imaging innovations that transform the clinician experience and drive smarter care. Turning knowledge into action, AGFA delivers advancements which empower radiologists with seamless workflows, intelligent automation and tailored diagnostic environments. Under the event 2026 theme "Rays of Knowledge", AGFA is ready to demonstrate how we have reached the summit of Empowerer - adopting the ‘Clinician-First' approach, which demonstrates a profound understanding of the clinician's challenges and workflow realities. "Clinician First is more than a message - it's a mindset", says Andrea Polticchia, Regional President for Southern Europe, AGFA HealthCare. "This approach reflects ou

Datavault AI Announces it has Developed Patented AI Rating Technology Launching Globally with Fintech.TV in Pilot Season14.1.2026 15:15:00 CET | Press release

Introducing AI Content Detection, Real-Time Bias Meter and Breakthrough Interactive Polling Powered by ADIO® PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 14, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today announced a transformative integration of its patented content detection, identification, and rating system (US Patent Publication 2019/0082224 A1) with Fintech.TV, the premier on-demand platform for fintech and AI news. This collaboration leverages Datavault AI's proprietary innovations to enhance viewer engagement and promote fair, balanced media through a revolutionary high performance computation and real-time bias meter and interactive polling utility that is activated via Datavault AI's patented Inaudible Tone® technology known as ADIO. Vince Molinari, CEO of Fintech.tv stated, "Fintech TV is known for exploring cutting-edge technology at the intersection of finance,

Skymantics Announces Strategic Investment and Technology Partnership with Geo Orchestration AI to Advance Generative Risk Analytics14.1.2026 13:30:00 CET | Press release

ZARAGOZA, ES / ACCESS Newswire / January 14, 2026 / Skymantics, a leading provider of AI-driven data analytics solutions, is announcing a strategic partnership with Geo Orchestration AI, a generative AI orchestration engine provider for the healthcare analytics sector. The partnership includes an equity investment by Skymantics' leadership and the appointment of Antonio Correas, Skymantics Co-founder and Chief Growth Officer, to Geo Orchestration AI's Board of Directors. This collaboration marks a significant convergence of technologies, combining Skymantics' DataGenesis synthetic data platform with Geo Orchestration AI's generative orchestration engine, Anna. Building a Developer Ecosystem The partnership was showcased at the American Geophysical Union (AGU) Annual Meeting 2025 in New Orleans. During the event, Skymantics demonstrated local- and national-scale heat and air quality risk analytics solutions built directly upon the Anna platform. This demonstration validates Anna's capab

GA-ASI and USN Test Expanded Sonobuoy Dispensing System For MQ-9B SeaGuardian(R)13.1.2026 19:00:00 CET | Press release

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 13, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and the U.S. Navy continue to expand the Anti-Submarine Warfare (ASW) capability of the MQ-9B SeaGuardian® Unmanned Aircraft System (UAS). Flight test was performed on December 17 and featured Sonobuoy Dispensing System (SDS) pods, more than previously tested, doubling the number of sonobuoys available. "Expanding sonobuoy capacity, including Multi-static Active Coherent (MAC) technology for SeaGuardian, has been an integral part of our advanced ASW strategy to broaden and enhance search areas," said GA-ASI President David R. Alexander. "The wider maritime coverage our MQ-9B's ASW capability provides is extremely valuable to our customers." Sonobuoys are naval sensors that drop from an aircraft into the ocean and help detect submarines. The SeaGuardian deployed AN/SSQ-36 Bathythermal, AN/SSQ-53G Directional Frequency Analysis and Recording (DIFAR) (passive), and AN/SSQ-62F D

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye